TY  - BOOK
AU  - Hosono,Makoto
AU  - Chatal,Jean-François
ED  - SpringerLink (Online service)
TI  - Resistance to Ibritumomab in Lymphoma
T2  - Resistance to Targeted Anti-Cancer Therapeutics,
SN  - 9783319782386
AV  - RC261-271 
U1  - 614.5999 23
PY  - 2018///
CY  - Cham
PB  - Springer International Publishing, Imprint: Springer
KW  - Cancer research
KW  - Cancer Research
N1  - Acceso multiusuario; Clinical Use and Efficacy of Ibritumomab in B-cell Lymphoma -- Biology and Pathology of B-cell lymphoma -- Resistance to Y-90 Ibritumomab Tiuxetan Therapy -- Features of Ibritumomab as Radionuclide Therapy -- Radiological Evaluation of Response and Resistance of Ibritumomab -- Characteristics of Ibritumomab as Radionuclide Therapy Agent -- Resistance and Heterogeneity of Intratumoral Antibody Distribution -- Radiation Dosimetry in Ibritumomab Therapy -- Combining RAIT and immune-based therapies to overcome resistance in cancer? -- Prospects for enhancing efficacy of radioimmunotherapy -- Index
N2  - This volume, in discussing resistance to ibritumomab, will focus on the mechanism, hematological aspects, radiological and nuclear medicine aspects, and medical physics that deal with radiation dosimetry, and will outline future prospects for overcoming resistance and enhancing efficacy of ibritumomab
UR  - http://148.231.10.114:2048/login?url=https://doi.org/10.1007/978-3-319-78238-6
ER  -